Study guide
3.2 Liver Cirrhosis & Portal Hypertension
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
3.2 Liver Cirrhosis & Portal Hypertension
Key Takeaways Explain This Topic AI
Hepatic stellate cell (Ito cell) activation into collagen-producing myofibroblasts in the space of Disse represents the central cellular pathway in liver cirrhosis development.
Portal hypertension is defined by a Hepatic Venous Pressure Gradient (HVPG) >5 mmHg; clinical manifestations (varices, ascites) emerge when HVPG exceeds 10 mmHg.
Child-Pugh score assesses cirrhosis prognosis using 5 parameters: Serum Bilirubin, Serum Albumin, INR/PT, Ascites, and Hepatic Encephalopathy.
Primary prophylaxis for esophageal varices in high-risk patients consists of non-selective beta-blockers (propranolol, nadolol, carvedilol) or endoscopic variceal ligation (EVL).
Spontaneous Bacterial Peritonitis (SBP) is diagnosed by an ascitic fluid absolute polymorphonuclear (PMN) leukocyte count >=250/mm³ and requires immediate IV 3rd generation cephalosporin plus albumin infusion.
Last updated: July 2026
Liver Cirrhosis & Portal Hypertension
Liver cirrhosis is defined histologically as diffuse hepatic fibrosis accompanied by structurally abnormal regenerative nodule formation. It represents the common final pathway of chronic inflammatory liver diseases (e.g., chronic hepatitis B/C, alcohol-associated liver disease, non-alcoholic steatohepatitis/MASH). In UPSC CMS examinations, questions regularly test the cellular mechanism of fibrogenesis, hemodynamic thresholds of portal hypertension, Child-Pugh and MELD scoring systems, and the management of decompensations.
- Pathophysiology of Hepatic Fibrosis & Portal Hypertension
- 1. Cellular Mechanism of Fibrogenesis
Under normal conditions, Hepatic Stellate Cells (Ito cells) reside in the space of Disse (the extracellular area between hepatocytes and sinusoidal endothelial cells) and function as the primary storage site for Vitamin A (retinoid ester).
Upon chronic hepatocyte injury, reactive oxygen species (ROS) and inflammatory cytokines (predominantly Transforming Growth Factor-beta1 [TGF- β 1 \beta1 β 1 ] and PDGF) activate quiescent stellate cells.
Activated stellate cells transdifferentiate into proliferate, contractile myofibroblasts , losing Vitamin A droplets and secreting massive amounts of Type I and Type III collagen into the space of Disse.
This leads to capillarization of hepatic sinusoids (loss of endothelial fenestrations), markedly increasing intrahepatic vascular resistance.
2. Hemodynamics of Portal Hypertension
Portal Hypertension is evaluated hemodynamically via the Hepatic Venous Pressure Gradient (HVPG) , calculated as: HVPG = Wedged Hepatic Venous Pressure (WHVP) − Free Hepatic Venous Pressure (FHVP) \text{HVPG} = \text{Wedged Hepatic Venous Pressure (WHVP)} - \text{Free Hepatic Venous Pressure (FHVP)} HVPG = Wedged Hepatic Venous Pressure (WHVP) − Free Hepatic Venous Pressure (FHVP)
- HVPG Value Clinical Significance
- Normal 1–5 mmHg
- Portal Hypertension > 5 mmHg >5\text{ mmHg} > 5 mmHg
Clinically Significant Portal HTN (CSPH) ≥ 10 mmHg \ge 10\text{ mmHg} ≥ 10 mmHg (Threshold for varices formation and ascites development)
Variceal Rupture Threshold ≥ 12 mmHg \ge 12\text{ mmHg} ≥ 12 mmHg (High risk of acute active variceal hemorrhage)
- Prognostic Classification Systems
- Child-Pugh Scoring System (Child-Turcotte-Pugh)
Evaluates surgical risk and 1–2 year survival in cirrhosis using 5 variables (3 biochemical, 2 clinical):
- Parameter 1 Point 2 Points 3 Points
- Total Bilirubin (mg/dL) < 2.0 <2.0 < 2.0 2.0–3.0 > 3.0 >3.0 > 3.0
- Serum Albumin (g/dL) > 3.5 >3.5 > 3.5 2.8–3.5 < 2.8 <2.8 < 2.8
INR (or PT prolongation) < 1.7 <1.7 < 1.7 ( < 4 s <4\text{ s} < 4 s ) 1.7–2.3 (4–6 s) > 2.3 >2.3 > 2.3 ( > 6 s >6\text{ s} > 6 s )
- Ascites None Mild / Controlled by diuretics Moderate to Severe / Refractory
- Hepatic Encephalopathy None Grade I–II (Mild) Grade III–IV (Severe)
- Child-Pugh Class A: 5–6 points (Well-compensated; 100% 1-year survival)
- Child-Pugh Class B: 7–9 points (Significant functional compromise; 80% 1-year survival)
- Child-Pugh Class C: 10–15 points (Decompensated; 45% 1-year survival)
- MELD-Na Score (Model for End-Stage Liver Disease)
Utilized for organ allocation in liver transplantation. Calculated using logarithmic equations of four objective serum variables: Bilirubin, Serum Creatinine, INR, and Serum Sodium .
- Complications of Portal Hypertension & Management
- 1. Esophageal & Gastric Varices
Primary Prophylaxis (Prevention of First Bleed): Indicated in patients with medium/large varices or small varices with red wale markings / Child-Pugh C.
Non-selective β \beta β -blockers ( Propranolol , Nadolol , or Carvedilol ): Reduce portal inflow via β 1 \beta_1 β 1 -adrenergic blockade (decreased cardiac output) and β 2 \beta_2 β 2 -blockade (unopposed α 1 \alpha_1 α 1 vasoconstriction of splanchnic circulation).
Endoscopic Variceal Ligation (EVL): Preferred if β \beta β -blockers are contraindicated or non-tolerated.
Acute Variceal Bleed Protocol:
Vasoactive therapy: Terlipressin (synthetic vasopressin analog; selective splanchnic vasoconstrictor), Somatostatin, or Octreotide given immediately.
Prophylactic IV Antibiotics: Ceftriaxone 1g IV daily for 7 days (reduces bacterial translocation, SBP risk, rebleeding, and mortality).
Urgent EGD within 12 hours: Perform EVL.
Rescue Therapy: Transjugular Intrahepatic Portosystemic Shunt (TIPS) creates a low-resistance conduit between the hepatic vein and portal vein branch, reducing HVPG below 12 mmHg.
2. Ascites & Spontaneous Bacterial Peritonitis (SBP)
Diagnostic Evaluation of Ascites: Paracentesis with Serum-Ascites Albumin Gradient (SAAG) calculation: SAAG = Serum Albumin concentration − Ascitic Fluid Albumin concentration \text{SAAG} = \text{Serum Albumin concentration} - \text{Ascitic Fluid Albumin concentration} SAAG = Serum Albumin concentration − Ascitic Fluid Albumin concentration
SAAG ≥ 1.1 g/dL \ge 1.1\text{ g/dL} ≥ 1.1 g/dL (High SAAG): Indicates Portal Hypertension (e.g., Cirrhosis, Cardiac ascites, Budd-Chiari syndrome).
SAAG < 1.1 g/dL < 1.1\text{ g/dL} < 1.1 g/dL (Low SAAG): Non-portal hypertension etiologies (e.g., Peritoneal carcinomatosis, Tuberculous peritonitis, Nephrotic syndrome, Pancreatitis).
Spontaneous Bacterial Peritonitis (SBP):
Bacterial infection of ascitic fluid without an intra-abdominal surgically treatable source of infection (most common organisms: E. coli , Klebsiella pneumoniae , Pneumococcus ).
Diagnostic criteria: Ascitic fluid Polymorphonuclear (PMN) leukocyte count ≥ 250 cells/mm 3 \ge 250\text{ cells/mm}^3 ≥ 250 cells/mm 3 ( 0.25 × 10 9 / L 0.25 \times 10^9/\text{L} 0.25 × 1 0 9 / L ).
Treatment: IV 3rd generation cephalosporin ( Cefotaxime 2g IV q8h or Ceftriaxone) PLUS IV Albumin ( 1.5 g/kg 1.5\text{ g/kg} 1.5 g/kg on Day 1 and 1.0 g/kg 1.0\text{ g/kg} 1.0 g/kg on Day 3) to preserve renal perfusion and prevent Type 1 Hepatorenal Syndrome.
3. Hepatic Encephalopathy (HE)
Reversible neuropsychiatric impairment caused by accumulation of gut-derived neurotoxins (chiefly ammonia [ NH 3 \text{NH}_3 NH 3 ] ) bypassing hepatic clearance due to portosystemic shunting and hepatocellular insufficiency.
Precipitating Factors: GI bleeding, infection/SBP, constipation, hypokalemic metabolic alkalosis, overuse of sedatives, hyponatremia.
West Haven Criteria: Grade I (trivial lack of awareness, euphoria/anxiety), Grade II (lethargy, disorientation, asterixis / flapping tremor ), Grade III (somnolence, stupor, gross disorientation), Grade IV (coma).
Treatment:
Lactulose (First-line): Synthetic non-absorbable disaccharide converted by colonic flora into lactic and acetic acids. Acidifies colonic lumen ( pH < 5.0 \text{pH} < 5.0 pH < 5.0 ), converting diffusable NH 3 \text{NH}_3 NH 3 into non-absorbable ammonium ( NH 4 + \text{NH}_4^+ NH 4 + ) ion ("ammonia trapping"). Promotes osmotic catharsis (titrate to 2–3 soft stools/day).
Rifaximin (Second-line / Add-on): Non-absorbable oral antibiotic (550 mg BID) that eliminates ammoniagenic gut bacteria.
4. Hepatorenal Syndrome (HRS)
Functional renal failure in advanced cirrhosis caused by extreme splanchnic arterial vasodilation → \rightarrow → severe renal vasoconstriction.
Diagnostic Criteria: Cirrhosis with ascites, serum creatinine > 1.5 mg/dL >1.5\text{ mg/dL} > 1.5 mg/dL , no response after 48 hours of diuretic withdrawal and IV albumin expansion ( 1 g/kg/day 1\text{ g/kg/day} 1 g/kg/day ), absence of shock, proteinuria < 500 mg/day <500\text{ mg/day} < 500 mg/day , and no parenchymal renal disease.
Treatment: Terlipressin IV + Albumin IV ; definitive treatment is orthotopic liver transplantation.